drug: risperidone
- Clinical class: atypical antipsychotic, neuroleptic
- Action: dopamine type 2 and serotonin type 2 antagonist
- Chemical class: benzisoxazole derivative
- Active metabolite: 9-hydroxy
- CSA schedule: none
- DEA number: none
- MEDLINEplus® Drug Information
U.S. Preparations:
- Risperdal® (Janssen)
FDA approved for:
12.29.1993 Schizophrenia
6.10.1996 treatment of psychotic manifestations of mental disorders (solution)
4.2.2003 (orally disintegrating tablets)
12.04.2003 short-term treatment of acute manic or mixed episodes associated with Bipolar I Disorder (as monotherapy or short-term combination therapy with lithium or valproate)
10.6.2006 treatment of irritability associated with Autistic Disorder in children and adolescents, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods.
8.22.2007 treatment of schizophrenia in adults and adolescents aged 13-17 years
8.22.2007 alone, or in combination with lithium or valproate, for the short-term treatment of acute manic or mixed episodes associated with Bipolar I Disorder in adults, and alone in children and adolescents aged 10-17 years
8.22.2007 Treatment of irritability associated with autistic disorder in children and adolescents aged 5-16 years
U.S. Prescribing Information
- Risperdal® Consta™ (Janssen) FDA approved for: 10.29.2003 treatment of psychotic manifestations of mental disorders
- Risperdal® M-TAB (Janssen)
Preparations Outside U.S.:
- Belivon, Risperin, Rispolept, Rispolin
Stephen Stahl's Clinical Pearls* (Consult your physician before making any change in your treatment.)
- Well accepted for treatment of agitation and aggression in elderly demented patients
- Well accepted for treatment of bipolar disorders and schizophrenia
- Many anecdotal reports of use in children and treatment refractory cases, and for positive symptoms of psychosis in disorders other than schizophrenia
- Only atypical antipsychotic that elevates prolactin levels, although this is of unproven and uncertain clinical significance
- Although low doses cause no more EPS than placebo, this does not mean that they never cause EPS
- Less weight gain than with some other antipsychotics, although this does not mean that there is never weight gain
| Books and Other Media: Follow the hypertext link to purchase items online. |
|
*Reprinted with permission from: Stahl, Stephen M Psychopharmacology of Antipsychotics Paperback 1999 Martin Dunitz, Ltd You cannot fully appreciate this book until you have seen the extraordinary illustrations of every aspect of this area of psychopharmacology and neurochemistry. Loaded with practical clinical "pearls."
